Grazoprevir, Elbasvir Combo Effective in Treatment-Naïve Patients With HCV Genotype 1b

October 25, 2017

By Andrew D. Bowser

WASHINGTON, DC -- October 25, 2017 -- Eight weeks of treatment with grazoprevir and elbasvir produced high rates of sustained virologic response at 12 weeks (SVR12) in patients with hepatitis C virus (HCV) genotype 1b with non-severe fibrosis, according to a study presented here at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

However, the results are preliminary, with data on only 53 out of a planned 120 patients.

“We must wait to see all the data,” said Armando Abergel, MD, CHU Estaing, Clermont-Ferrand, France.

Enrolment was limited to patients with HCV genotype 1b with non-severe (stage F0-F2) fibrosis. The 53 patients in the study to date received the fixed-dose combination, comprised of grazoprevir 100 mg and elbasvir 50 mg daily for 8 weeks.

Of the 53 patients, 98% had SVR at 4 weeks and 96% achieved SVR12.

The 8-week regimen was well tolerated with a favourable safety profile. There were no grade 3 or 4 adverse events reported, and the main treatment-related adverse events were asthenia, headache, and digestive issues.

The researchers noted the significance of the 8-week dosing period with grazoprevir/elbasvir, saying that reduced HCV treatment duration might improve adherence while reducing drug exposure.

HCV genotype 1b is the most common HCV subtype in the world, responsible globally for about 22% of all infections.

[Presentation title: High Efficacy and Safety of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, Non-Severe Fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER Study. Abstract LB-5]

Like this story?
Log in or register to post comments

DG News lets you be the first to know advances in medical research, results from conferences, and changes in healthcare policy and business.